genomics

Cathie Wood‘s Ark Invest makes trades across its ETFs every trading day. Those trades are sometimes closely monitored by investors when they involve new stock picks or large trades. For a small diagnostic testing company, Wood’s buying the stock for seven straight market days should put...

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes for 2026 that investors should watch. This year's list comes after the firm reported a strong 2025, with its ETFs outperforming the S&P 500. Ark Invest Big Ideas 2026 List Ark Invest’s highly...

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the definitive coming-out party for the genomic revolution.  PACB stock is up. See the chart and price action here.  As 2025 draws to a close, ARK aggressively trimmed legacy winners...

Ark Invest CEO Cathie Wood is doubling down on genomics. What Happened: Pacific Biosciences of California Inc. (NASDAQ:PACB), known as PacBio, is biotech’s new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios. ARK...

Chip supplier Nvidia Corp (NASDAQ: NVDA) on Tuesday launched Cambridge-1, which it claims is the fastest supercomputer in the United Kingdom, dedicated to the healthcare industry. What Happened: With a $100 million investment behind it, Nvidia has opened access to Cambridge-1 to scientists,...

Cathie Wood-led Ark Investment Management has quickly piled up over one million shares in the semiconductor company Quantum-Si Inc (NASDAQ: QSI) since it began trading earlier this month. The popular investment firm on Thursday snapped another 95,199 shares, estimated to be worth about $1 million,...

A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp...

Special purpose acquisition companies (SPACs) were a hot topic for investors in 2020 and continue to be a big story in 2021. While SPACs have lost some of the initial buzz surrounding them, some of the larger names going public via this method are attracting interest from mutual funds and ETFs. Ark...

Ark Funds hosted an investor webinar Tuesday, sharing ideas on several industries and portfolio components, including a discussion on some names in the genomics space. Ark Funds On Genomics: Ark Funds is well-known for its bullish thesis on the genomics market. The company has the Ark...

Personalized DNA testing company 23andMe is going public with a SPAC deal announced Thursday. The SPAC Deal: 23andMe is going public with VG Acquisition Corp (NYSE: VGAC), a SPAC from Virgin Group. The deal values 23andMe at $3.5 billion. A $250-million PIPE includes $25-million investments from...

One of the hottest names in the investing world in 2020 was Cathie Wood, CEO of Ark Funds. The legendary fund manager had some of the best performing ETFs of the year and also saw strong inflows of money put into her actively managed funds. Ark Funds recently shared their "Big Ideas...

Some of the best performing ETFs in 2020 have been the Ark Funds, actively managed ETFs led by Cathie Wood. A long-time Tesla Inc (NASDAQ: TSLA) and technology stock bull, Wood is now betting heavily on genomic stocks. Wood On Genomics: Genomic stocks are expected to drive strong returns for the...

Since the completion of the National Institutes of Health and Department of Energy-funded Human Genome Project in 2003, genomics has been one of the most compelling areas of the biotechnology universe. Genomics investing is now more accessible thanks to Tuesday's debut of the Global X Genomics...